bullish
Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound
400 Views12 Feb 2025 10:44
Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
What is covered in the Full Insight:
- Introduction
- Company Background
- Recent Performance and Expansion
- Financial Highlights
- Conclusion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (17th Feb 2025) - CATL, Hengrui, Mixue, Guming, Hexaware, Ajax, Aegis, Daiichi, Takasago17 Feb 2025
- Hengrui (恒瑞医药) A/H Listing: A Worthy Comparison with Hansoh Pharma13 Feb 2025
- CATL A/H Listing - IPO Filing Updates13 Feb 2025
- Foshan Haitian Flavouring A/H Listing - Strong Brand but Sales Have Been Slowing Down05 Feb 2025
- CATL A/H Listing - Early Look - US$5bn Could Be Hong Kong’s Largest This Year21 Jan 2025
- Midea A/H Listing - Bigger Deal, Better Pricing09 Sep 2024
x